摘要
酶催化黄嘌呤氧化还原酶(XOR)在最高灵长类动物中最后两步嘌呤分解代谢步骤。黄嘌呤氧化还原酶是哺乳动物的脱氢酶活性酶,在各种病理生理条件下可转换为氧化酶活性。酶催化黄嘌呤氧化还原酶活性的转录和翻译后的水平,可能会从细胞毒性到炎症生成活性氧和氮的物种高度管制,引发不同的后果。底物特异性低代谢使酶催化黄嘌呤氧化还原酶代谢成一些内源性代谢物和各种外源性化合物,包括黄嘌呤氧化还原酶表达。 本文重点综述异或作为药物代谢酶的作用,特别是对于药物的抗癌、抗菌、抗病毒、免疫抑制剂或血管扩张活动,以及作用于代谢或药物诱导黄嘌呤氧化还原酶表达。 黄嘌呤氧化还原酶有激活作用,对醌类药物喹赛多,抗病毒的核苷类似物,别嘌呤醇,硝酸盐和亚硝酸盐的药理作用很重要。黄嘌呤氧化还原酶活性对吡嗪酸,甲基黄嘌呤和甲苯磺丁脲有降解功能,其半衰期可通过黄嘌呤氧化还原酶抑制剂的使用寿命。 总之,为了避免潜在的药物相互作用的风险,如药物的生物利用度或失去药效毒性过量,注意是黄嘌呤氧化还原酶抑制剂的使用建议,在痛风或高尿酸血症患者肿瘤溶解综合征的影响的情况下,当需要同时管理被激活或被药物代谢活性的异或退化治疗物质。
关键词: 抗癌药物,抗菌药物,免疫抑制药物,硝基血管扩张剂,嘌呤类似物,黄嘌呤氧化还原酶。
Current Medicinal Chemistry
Title:Xanthine Oxidoreductase in Drug Metabolism: Beyond a Role as a Detoxifying Enzyme
Volume: 23 Issue: 35
Author(s): Maria Giulia Battelli, Letizia Polito, Massimo Bortolotti, Andrea Bolognesi
Affiliation:
关键词: 抗癌药物,抗菌药物,免疫抑制药物,硝基血管扩张剂,嘌呤类似物,黄嘌呤氧化还原酶。
摘要: The enzyme xanthine oxidoreductase (XOR) catalyzes the last two steps of purine catabolism in the highest uricotelic primates. XOR is an enzyme with dehydrogenase activity that, in mammals, may be converted into oxidase activity under a variety of pathophysiologic conditions. XOR activity is highly regulated at the transcriptional and post-translational levels and may generate reactive oxygen and nitrogen species, which trigger different consequences, ranging from cytotoxicity to inflammation. The low specificity for substrates allows XOR to metabolize a number of endogenous metabolites and a variety of exogenous compounds, including drugs.
The present review focuses on the role of XOR as a drug-metabolizing enzyme, specifically for drugs with anticancer, antimicrobial, antiviral, immunosuppressive or vasodilator activities, as well as drugs acting on metabolism or inducing XOR expression.
XOR has an activating role that is essential to the pharmacological action of quinone drugs, cyadox, antiviral nucleoside analogues, allopurinol, nitrate and nitrite. XOR activity has a degradation function toward thiopurine nucleotides, pyrazinoic acid, methylxanthines and tolbutamide, whose half-life may be prolonged by the use of XOR inhibitors.
In conclusion, to avoid potential drug interaction risks, such as a toxic excess of drug bioavailability or a loss of drug efficacy, caution is suggested in the use of XOR inhibitors, as in the case of hyperuricemic patients affected by gout or tumor lysis syndrome, when it is necessary to simultaneously administer therapeutic substances that are activated or degraded by the drug-metabolizing activity of XOR.
Export Options
About this article
Cite this article as:
Maria Giulia Battelli, Letizia Polito, Massimo Bortolotti, Andrea Bolognesi , Xanthine Oxidoreductase in Drug Metabolism: Beyond a Role as a Detoxifying Enzyme, Current Medicinal Chemistry 2016; 23 (35) . https://dx.doi.org/10.2174/0929867323666160725091915
DOI https://dx.doi.org/10.2174/0929867323666160725091915 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Atorvastatin Prevents the Neuron Loss in the Hippocampal Dentate Gyrus Region through its Anti-Oxidant and Anti-Apoptotic Activities
CNS & Neurological Disorders - Drug Targets The Role of Dietary Polyphenols in the Management of Inflammatory Bowel Disease
Current Pharmaceutical Biotechnology Periodontitis and Redox Status: A Review
Current Pharmaceutical Design Neurocognitive Monitoring and Care During Pediatric Cardiopulmonary Bypass — Current and Future Directions
Current Cardiology Reviews Regulatory Role of Anesthetics on Heme Oxygenase-1
Current Drug Targets Polymeric Nanocarriers and Nanoreactors: A Survey of Possible Therapeutic Applications
Current Pharmaceutical Design Endothelial Chemokines in Autoimmune Disease
Current Pharmaceutical Design Lipid Rafts and Redox Regulation of Cellular Signaling in Cholesterol Induced Atherosclerosis
Current Cardiology Reviews Gender Differences in Non-Obstructive Coronary Artery Disease
Current Pharmaceutical Design Topical Antimicrobials for Burn Wound Infections
Recent Patents on Anti-Infective Drug Discovery Dynorphins in Development and Disease: Implications for Cardiovascular Disease
Current Molecular Medicine Effects of Glucagon-like Peptide-1 Receptor Agonists and Sodium-glucose Cotransporter 2 Inhibitors on Cardiorenal and Metabolic Outcomes in People Without Diabetes
Current Pharmaceutical Design Antioxidant Therapy and Drugs Interfering with Lipid Metabolism: Could They Be Effective in NAFLD Patients?
Current Pharmaceutical Design Tissue Engineering for Post-Myocardial Infarction Ventricular Remodeling
Mini-Reviews in Medicinal Chemistry Application of VEGF Gene Therapy in Two Basic Fields of Plastic- Reparative Surgery: Tissue Reconstruction with Flaps and Peripheral Nerve Surgery
Recent Patents on Regenerative Medicine Differential Regulation of microRNAs in Patients with Ischemic Stroke
Current Neurovascular Research Anesthetic Cardioprotection in Relation to Mitochondria: Basic Science
Current Pharmaceutical Design Design and Development of Nanovehicle-Based Delivery Systems for Preventive or Therapeutic Supplementation with Flavonoids
Current Medicinal Chemistry Glucagon and Glucagon-Like Peptide Receptors as Drug Targets
Current Pharmaceutical Design Addressing Alzheimer’s Disease and Cognitive Loss through Autophagy
Current Neurovascular Research